- Home
- ZNTL vs CCIF Comparison
ZNTL vs CCIF Comparison
Compare ZNTL & CCIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- CCIF
- Stock Information
- Founded
- ZNTL 2014
- CCIF 2011
- Country
- ZNTL United States
- CCIF United States
- Employees
- ZNTL N/A
- CCIF N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- CCIF Finance/Investors Services
- Sector
- ZNTL Health Care
- CCIF Finance
- Exchange
- ZNTL Nasdaq
- CCIF Nasdaq
- Market Cap
- ZNTL 102.2M
- CCIF 113.2M
- IPO Year
- ZNTL 2020
- CCIF N/A
- Fundamental
- Price
- ZNTL $1.23
- CCIF $6.63
- Analyst Decision
- ZNTL Buy
- CCIF
- Analyst Count
- ZNTL 8
- CCIF 0
- Target Price
- ZNTL $8.53
- CCIF N/A
- AVG Volume (30 Days)
- ZNTL 752.0K
- CCIF 76.9K
- Earning Date
- ZNTL 05-20-2025
- CCIF 01-01-0001
- Dividend Yield
- ZNTL N/A
- CCIF 25.90%
- EPS Growth
- ZNTL N/A
- CCIF N/A
- EPS
- ZNTL N/A
- CCIF N/A
- Revenue
- ZNTL $67,425,000.00
- CCIF N/A
- Revenue This Year
- ZNTL N/A
- CCIF N/A
- Revenue Next Year
- ZNTL N/A
- CCIF N/A
- P/E Ratio
- ZNTL N/A
- CCIF N/A
- Revenue Growth
- ZNTL N/A
- CCIF N/A
- 52 Week Low
- ZNTL $1.01
- CCIF $7.43
- 52 Week High
- ZNTL $13.24
- CCIF $10.16
- Technical
- Relative Strength Index (RSI)
- ZNTL 38.08
- CCIF 41.84
- Support Level
- ZNTL $1.33
- CCIF $6.55
- Resistance Level
- ZNTL $1.32
- CCIF $6.85
- Average True Range (ATR)
- ZNTL 0.10
- CCIF 0.14
- MACD
- ZNTL -0.00
- CCIF 0.02
- Stochastic Oscillator
- ZNTL 8.22
- CCIF 40.56
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About CCIF Carlyle Credit Income Fund Shares of Beneficial Interest
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.